EQUITY RESEARCH - COMPANY REPORT

MASTER TB MASTER STYLE

THAILAND / SERVICES



UNCHANGED

TARGET PRICE THB82.00 **CLOSE** THB72.75 **UP/DOWNSIDE** +12.7% **PRIOR TP** THB71.00 **CHANGE IN TP** +15.5% TP vs CONSENSUS +3.2%

Continuing to invest in more deals

- MASTER announced a second stock dividend payment with the intention to submit a request to transfer to the SET.
- Revise up our 2024E profit by 16% to surge 49% y-y.
- Maintain BUY with a solid net profit growth outlook and strong balance sheet.

Ending 2023 with impressive results

MASTER reported a record high 4Q23 net profit of THB164m (+64% q-q, +108% y-y). We are impressed by the new operating-hour high at 14,316 hours (+13.7% q-q), implying a utilization rate of 73.8% (vs 64.9% in 3Q23). Its 4Q23 gross margin soared to 63.6% from 58.2% in 3Q23. supported by higher operating leverage. The company began to recognize profit sharing from four companies, totaling THB5m. At the end of 2023, MASTER achieved a record high profit of THB416m, an increase of 38% y-y.

Preparing to move to the SET; announced additional deals

The company announced a stock dividend at 1:0.142857, resulting in an increase of 301.71 million shares after the ex-dividend date on 4 Mar 2024. Following this, the company will prepare to apply to move to the SET. In addition, MASTER announced four more investment deals worth a total of THB152m. These include 1) a 20% stake in Aesthelis Code - a medical-grade silicone manufacturer; 2) a 35% stake in Me Center Clinic - a mental health clinic; 3) a 40% stake in Aurora Clinic - a cosmetic surgery clinic with two branches; and 4) a 15% stake in Korawin Holding - Korawin Clinic and Ronnapee Clinic. We expect MASTER to recognize a share profit from these four deals starting from 3Q24 onward.

Revise up our 2024 profit forecast with dramatic growth

We maintain our bullish view of MASTER's 2024 growth outlook due to organic growth, i.e. the full-year realization of its new operating beds and goal to increase foreign customer contributions to c30% of total revenue from 26% in 4Q23. There would also be inorganic drivers, such as the realization of profit sharing from 14 companies. We have increased 2024-25E profit sharing by 19-22% to THB125m and THB137m, representing roughly 20% of the 2024-25E net profit. Thus, we revise up our 2024-25E net profit by 16% and 13% to grow by 49% y-y and 10% y-y, respectively.

Our new TP is THB82 before XD and THB72 after XD

Following the earnings revisions, we revise up our target price to THB82 before XD and THB72 after XD (35x 2024E P/E, maintained). The pre-XD target price has a potential upside of 12.7%. In the short term, we expect its 1Q24 profit to decline due to the low season, while the downside risk is that its share of profits might be lower than expected.

KEY STOCK DATA

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	1,917	2,326	2,556	2,861
Net profit	416	621	685	763
EPS (THB)	1.58	2.35	2.60	2.89
vs Consensus (%)	-	63.0	30.0	21.3
EBITDA	586	719	800	902
Recurring net profit	416	621	685	763
Core EPS (THB)	1.58	2.35	2.60	2.89
Chg. In EPS est. (%)	nm	16.0	12.9	nm
EPS growth (%)	(2.2)	49.2	10.3	11.3
Core P/E (x)	46.1	30.9	28.0	25.2
Dividend yield (%)	0.4	1.0	1.4	1.5
EV/EBITDA (x)	32.2	26.7	23.7	20.7
Price/book (x)	6.4	5.6	5.0	4.5
Net debt/Equity (%)	(11.1)	(0.1)	(5.7)	(12.6)
ROE (%)	24.5	19.4	18.9	18.8



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	13.7	36.6	5.6
Relative to country (%)	11.4	38.2	25.4
Mkt cap (USD m)			532
3m avg. daily turnover (USD m)			2.8
Free float (%)			0
Major shareholder	Mascl	namadol fa	mily (68%)
12m high/low (THB)		8	3.18/41.50
Issued shares (m)			264.00

Sources: Bloomberg consensus; FSSIA estimates



Sureeporn Teewasuwet Fundamental Investment Analyst on Securities: License no. 040694 sureeporn.t@fssia.com, +66 2646 9972

Investment thesis

We expect Thailand's cosmetic surgery market to grow by 9.7% CAGR in 2023-30, close to global cosmetic surgery markets. Additionally, the medical tourism trend should support surgery hospitals in Thailand to have a higher revenue mix from international customers, which would in turn support future growth.

MASTER has several strengths. It has earned a good reputation and has become well-known over the past ten years. Given the experience of Dr. Raweewat Maschamadol and other renowned doctors, MASTER has gained customer trust, leading to referrals and positive reviews on social media. It has also expanded and invested in other businesses to further its long-term growth.


Company profile

MASTER is in the cosmetic surgery hospital business under Masterpiece Hospital. Established in 2012, it has 17 operating beds and offers one-stop cosmetic surgery services. MASTER earns revenue from four services, including surgery, skin, hair treatment, and aftercare, with surgery contributing the highest revenue of 81% of total revenue.

www.masterpiecehospital.com

Principal activities (revenue, 2023)

- Surgery 81.0 %
- Skin 7.1 %
- Hair treatment 6.0 %
- Aftercare 3 6 %
- Others 2.3 %




Source: Master Style

Major shareholders

■ Maschamadol family - 68.0 %

■ Others - 32.0 %



Source: Master Style

Catalysts

2024 potential growth drivers include 1) more surgery customers; 2) a higher utilization rate for operating beds, which would drive operating leverage; and 3) the realization of profit and synergies from M&As.

Risks to our call

Downside risks to our P/E-based TP include 1) increased competition; 2) a pandemic that results in a lockdown; 3) lower-than-expected utilization rate of new operating beds; 4) higher-than-expected doctor costs and expenses; and 5) a loss contribution from the acquired units.

Event calendar

Date	Event
May 2024	1Q24 results announcement

Key assumptions

	2024E	2025E	2026E
Total OR rooms (no.)	17	17	17
Capacity hours (hours)	80,665	80,665	80,665
Operating hours (hours)	58,079	60,499	64,532
Utilization rate (%)	72.0	75.0	80.0

Source: FSSIA estimates

Earnings sensitivity

- For every 5% increase in revenue, we estimate 2024 net profit to rise by 3.9%, and vice versa, all else being equal.
- For every 0.5% increase in GPM, we estimate 2024 net profit to rise by 2%, and vice versa, all else being equal.
- For every 1% increase in SG&A, we estimate 2024 net profit to fall by 3.5%, and vice versa, all else being equal.

Source: FSSIA estimates

Exhibit 1: MASTER – 4Q23 earnings results

	4Q22	1Q23	2Q23	3Q23	4Q23	Char	nge	2022	2023	Change
	(THB m)	(q-q%)	(y-y%)	(THB m)	(THB m)	(y-y%)				
Sales	471	436	459	479	543	13.2	15.1	1,483	1,917	29.3
Cost of sales	210	182	204	200	198	(1.4)	(5.7)	641	785	22.4
Gross profit	262	253	255	279	345	23.7	31.8	841	1,132	34.5
SG&A	161	162	158	160	154	(4.1)	(4.7)	463	634	37.0
Operating profit	103	94	106	128	197	53.3	91.6	386	525	35.9
Profit sharing	0	0	0	0	5	nm	nm	0	5	nm
Interest expense	3	3	4	4	3	(5.4)	(4.7)	9	14	51.5
Tax expense	21	19	21	25	40	60.0	95.3	76	105	37.3
Reported net profit	79	72	81	100	164	63.8	107.8	301	416	38.4
Core profit	79	72	81	100	164	63.8	107.8	301	416	38.4
Key Ratios (%)						(ppt)	(ppt)			
Gross margin	55.5	58.2	55.5	58.2	63.6	5.4	8.0	56.7	59.1	2.3
SG&A to sales	34.2	37.2	34.3	33.5	28.3	(5.1)	(5.9)	31.2	33.1	1.9
Operating margin	21.8	21.5	23.1	26.8	36.3	9.5	14.5	26.1	27.4	1.3
Net margin	16.7	16.4	17.7	20.8	30.1	9.3	13.4	20.3	21.7	1.4
Core margin	16.7	16.4	17.7	20.8	30.1	9.3	13.4	20.3	21.7	1.4
Operating Statistics										
Revenue breakdown (THB m)										
Surgery	389	340	364	387	462	19.3	18.9	1,194	1,553	30.1
Skin	38	42	34	33	27	(17.4)	(28.2)	106	136	28.4
Hair treatment	21	28	32	31	24	(23.3)	12.3	90	115	27.8
Aftercare	18	18	18	17	17	3.1	(2.3)	62	70	11.9
Other	6	8	11	11	13	9.9	96.0	31	44	40.3


Source: MASTER

Exhibit 2: Changes in key assumptions for MASTER

		Forecast			Previous		Change		
	2024E	E 2025E 2026E 2024E 2025E			2025E	2026E	2024E	24E 2025E 20	
	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(%)	(%)	(%)
Total revenue	2,326	2,556	2,861	2,216	2,517	2,842	5.0	1.5	0.7
Costs	949	1,038	1,159	920	1,040	1,165	3.2	(0.2)	(0.6)
Gross profit	1,377	1,518	1,702	1,296	1,478	1,677	6.2	2.8	1.5
SG&A expense	768	844	944	731	831	938	5.0	1.5	0.7
Interest expense	15	15	15	14	13	12	6.3	11.9	18.1
Profit sharing	125	137	144	105	112	124	19.0	22.3	16.1
Reported net profit	621	685	763	536	607	703	16.0	12.9	8.5
Core profit	621	685	763	536	607	703	16.0	12.9	8.5
Key ratios (%)									
Total revenue growth	21.4	9.9	11.9	15.6	13.6	12.9			
Net profit growth	49.2	10.3	11.3	28.7	13.3	15.9			
Core profit growth	49.2	10.3	11.3	28.7	13.3	15.9			
Gross margin	59.2	59.4	59.5	58.5	58.7	59.0	0.7	0.7	0.5
SG&A to sales	33.0	33.0	33.0	33.0	33.0	33.0	0.0	0.0	0.0
Net margin	26.7	26.8	26.7	24.2	24.1	24.7	2.5	2.7	1.9
Core margin	26.7	26.8	26.7	24.2	24.1	24.7	2.5	2.7	1.9
Profit sharing to net profit	20.1	20.0	18.9	19.6	18.5	17.6	0.5	1.5	1.2
Operating statistics									
Total OR rooms (no.)	17	17	17	17	17	17	0.0	0.0	0.0
Capacity hours (hours)	80,665	80,665	80,665	88,330	88,330	88,330	(8.7)	(8.7)	(8.7)
Operating hours (hours)	58,079	60,499	64,532	54,272	58,866	63,460	7.0	2.8	1.7
Utilization rate (%)	72.0	75.0	80.0	61.4	66.6	71.8	17.2	12.5	11.4


Source: FSSIA estimates

Exhibit 3: Operating hours and utilization rate




Sources: MASTER; FSSIA estimates

Exhibit 5: Total revenue and growth




Sources: MASTER; FSSIA estimates

Exhibit 7: Profit sharing and % to net profit



Sources: MASTER; FSSIA estimates

Exhibit 4: Revenue breakdown by service type




Sources: MASTER; FSSIA estimates

Exhibit 6: Gross margin and SG&A to sales



Sources: MASTER; FSSIA estimates

Exhibit 8: Net profit and growth



Sources: MASTER; FSSIA estimates

Financial Statements

Master Style

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	1,483	1,917	2,326	2,556	2,861
Cost of goods sold	(641)	(785)	(949)	(1,038)	(1,159)
Gross profit	841	1,132	1,377	1,518	1,702
Other operating income	8	27	33	33	37
Operating costs	(463)	(634)	(768)	(844)	(944)
Operating EBITDA	422	586	719	800	902
Depreciation	(35)	(62)	(77)	(92)	(107)
Goodwill amortisation	0	0	Ó	0	0
Operating EBIT	386	525	642	708	795
Net financing costs	(4)	(9)	(9)	(9)	(9)
Associates	Ô	5	125	137	144
Recurring non-operating income	0	5	125	137	144
Non-recurring items	0	0	0	0	0
Profit before tax	383	521	758	836	930
Тах	(76)	(105)	(136)	(150)	(167)
Profit after tax	306	416	621	685	763
Minority interests	-	-	-	-	
Preferred dividends	_	-	_	_	_
Other items	-	-	-	-	
Reported net profit	306	416	621	685	763
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	306	416	621	685	763
Per share (THB)	300	410	021	003	703
Recurring EPS *	1.61	1.58	2.35	2.60	2.89
Reported EPS	1.61	1.58	2.35	2.60	2.89
DPS	0.30	0.27	0.71	1.04	1.16
Diluted shares (used to calculate per share data)	190	264	264	264	264
Growth	190	204	204	204	204
Revenue (%)	124.8	29.3	21.4	9.9	11.9
Operating EBITDA (%)	73.9	39.1	22.5	11.3	12.8
Operating EBIT (%)	82.7	35.9	22.3	10.3	12.3
Recurring EPS (%)	0.0	(2.2)	49.2	10.3	11.3
Reported EPS (%)	0.0	(2.2)	49.2	10.3	11.3
Operating performance	0.0	(2.2)	49.2	10.5	11.0
Gross margin inc. depreciation (%)	56.7	59.1	59.2	59.4	59.5
	59.1	62.3	62.5	63.0	63.2
Gross margin exc. depreciation (%)	28.4		30.9		31.5
Operating EBITDA margin (%) Operating EBIT margin (%)	28.4 26.1	30.6	30.9 27.6	31.3	31.5 27.8
		27.4		27.7	
Net margin (%)	20.7	21.7	26.7	26.8	26.7
Effective tax rate (%)	19.9	20.1	18.0	18.0	18.0
Dividend payout on recurring profit (%)	18.6	17.0	30.0	40.0	40.0
Interest cover (X)	102.2	62.2	81.8	90.8	101.7
nventory days	26.8	41.1	42.8	42.0	41.8
Debtor days	0.9	1.1	1.1	1.0	0.0
Creditor days	34.7	64.9	62.6	47.2	47.0
Operating ROIC (%)	115.1	37.7	33.0	43.0	46.8
ROIC (%)	82.1	25.8	20.2	19.2	20.4
ROE (%)	107.4	24.5	19.4	18.9	18.8
ROA (%)	40.0	18.5	16.4	16.3	16.3
* Pre-exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Surgery	1,194	1,553	1,908	2,087	2,337
Skin	106	136	161	185	210
Hair treatment	90	115	136	154	175
Aftercare	62	70	75	82	88

Sources: Master Style; FSSIA estimates

Financial Statements

Master Style

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	306	416	621	685	763
Depreciation	35	62	77	92	107
Associates & minorities	0	0	0	0	C
Other non-cash items	0	(5)	(125)	(137)	(144)
Change in working capital	(100)	74	(38)	18	705
Cash flow from operations	242	547	534	658	735
Capex - maintenance	(413)	(2,179)	(673)	- (171)	(107)
Capex - new investment Net acquisitions & disposals	(413)	(2,179)	(073)	(171)	(107)
Other investments (net)	-	-	-	-	
Cash flow from investing	(413)	(2,179)	(673)	(171)	(107)
Dividends paid	(263)	(99)	(189)	(274)	(305)
Equity finance	198	2,270	0	0	(000)
Debt finance	159	(11)	(2)	(2)	(2)
Other financing cash flows	(1)	2	0	0	1
Cash flow from financing	93	2,161	(190)	(275)	(306)
Non-recurring cash flows	-	-	-	-	
Other adjustments	0	0	0	0	C
Net other adjustments	(5)	0	0	0	0
Movement in cash	(83)	529	(329)	212	321
Free cash flow to firm (FCFF)	(162.06)	(1,618.40)	(124.30)	501.30	641.77
Free cash flow to equity (FCFE)	(18.91)	(1,641.98)	(140.59)	485.66	626.34
Per share (THB)					
FCFF per share	(0.61)	(6.13)	(0.47)	1.90	2.43
FCFE per share	(0.07)	(6.22)	(0.53)	1.84	2.37
Recurring cash flow per share	1.80	1.79	2.17	2.42	2.75
Balance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Tangible fixed assets (gross) Less: Accumulated depreciation	498 (73)	1,242 (339)	1,578 (366)	1,665 (395)	1,740 (427)
Tangible fixed assets (net)	(73) 424	903	1,211	1,270	1,313
Intangible fixed assets (net)	7	7	7	7	7,313
Long-term financial assets	8	15	15	15	15
nvest. in associates & subsidiaries	0	362	1,861	2,019	2,060
Cash & equivalents	98	627	298	509	830
A/C receivable	5	7	6	7	8
nventories	63	101	104	114	127
Other current assets	166	1,136	302	281	315
Current assets	331	1,871	710	911	1,280
Other assets	177	480	233	256	286
Total assets	947	3,637	4,037	4,477	4,961
Common equity	404	2,991	3,424	3,835	4,292
Minorities etc.	0	0	0	0	C
Total shareholders' equity	404	2,991	3,424	3,835	4,292
Long term debt	291	294	292	291	289
Other long-term liabilities	3	5	5	5	6
Long-term liabilities	294	298	297	296	295
A/C payable	148	260	210	230	257
Short term debt	15	2	2	2	2
Other current liabilities	86	86	105	115	114
Current liabilities	249	348	316	347	373
Total liabilities and shareholders' equity	947	3,637	4,037	4,477	4,961
Net working capital	0	898	98	57	78
nvested capital Includes convertibles and preferred stock which is being	616 s treated as debt	2,664	3,424	3,623	3,758
	y irealed as debt				
Per share (THB)					
Book value per share	2.12	11.33	12.97	14.53	16.26
Tangible book value per share	2.09	11.30	12.94	14.50	16.23
Financial strength					
Net debt/equity (%)	51.7	(11.1)	(0.1)	(5.7)	(12.6
Net debt/total assets (%)	22.1	(9.1)	(0.1)	(4.8)	(10.9
Current ratio (x)	1.3	5.4	2.2	2.6	3.4
CF interest cover (x)	105.2	64.0	57.8	71.6	80.5
Valuation	2022	2023	2024E	2025E	2026E
Recurring P/E (x) *	45.1	46.1	30.9	28.0	25.2
Recurring P/E @ target price (x) *	50.9	52.0	34.8	31.6	28.4
Reported P/E (x)	45.1	46.1	30.9	28.0	25.2
Dividend yield (%)	0.4	0.4	1.0	1.4	1.5
	34.2	6.4	5.6	5.0	4.5
Price/book (x)			5.6	5.0	4.5
Price/tangible book (x)	34.8	6.4	5.0	5.0	7.0
Price/tangible book (x)	34.8 33.3	6.4 32.2	26.7	23.7	
Price/book (x) Price/tangible book (x) EV/EBITDA (x) ** EV/EBITDA @ target price (x) **					20.7

Sources: Master Style; FSSIA estimates

Disclaimer for ESG scoring

ESG score	Methodolog	у			Rating				
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process base from the ann	ed on the com ual S&P Glob	transparent, rules-based npanies' Total Sustainabi oal Corporate Sustainabili oanies within each industr	ility Scores resulting lity Assessment (CSA).	Sustainability Assessment (CSA) for DJSI. Companies with an S&P GI				
Sustainability Investment List (THSI) by The Stock Exchange of Thailand (SET)	managing bu Candidates r 1) no irregula float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with tr must pass the ar trading of the shareholders ome key disque pendent direct related to CG	oility in Environmental and ransparency in Governance preemptive criteria, with the board members and es, and combined holding uualifying criteria include: ctors and free float violation, social & environmental iterations in red for > 3 year	nce, updated annually. It wo crucial conditions: executives; and 2) free must be >15% of paid- 1) CG score of below on; 3) executives' impacts; 4) equity in	To be eligible for THSI inclusion, verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of D. during the assessment year. The scoring will be fairly weighted agains nature of the relevant industry and materiality.				
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by t Thailand (SE	he Thai IOD,	th in sustainable developi with support from the Sto Its are from the perspectives.	ock Exchange of	Good (80-89), 3 and not rated for equitable treatr	3 for Good (70 or scores belo nent of share 25%); 4) disclo	ories: 5 for Excel 0-79), 2 for Fair (0 w 50. Weightings holders (weight 2 osure & transpare	60-69), 1 for F s include: 1) th 5% combined	ass (60-69), ne rights; 2) and); 3) the role of
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment are transparent a out of five the criteria cover date (45%), a circulation of s exercised. The and verifiability	e incorporated and sufficiently e CG compon r AGM proced and after the r ufficient informa is second assess or, and 3) openne	which shareholders' rights d into business operation by disclosed. All form impunents to be evaluated annures before the meeting meeting (10%). (The first a stion for voting; and 2) facilitation for voting. The third involves, resolutions and voting reserved.	is and information is ortant elements of two nually. The assessment (45%), at the meeting assesses 1) advance ting how voting rights can be meetings; 2) transparency ses the meeting minutes that			o four categories: r (80-89), and not		. ,.
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishmer policies. The (Companies de Declaration of Certification, in managers and	nt of key contrest Certification is eciding to become Intent to kick off acluding risk assemployees, estimated.	Checklist include corrupti rols, and the monitoring a is good for three years. me a CAC certified member si if an 18-month deadline to sub sessment, in place of policy a tablishment of whistleblowing talkeholders.)	and developing of start by submitting a bmit the CAC Checklist for and control, training of	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.				
Morningstar Sustainalytics	based on an risk is unmar regulatory filing	assessment of naged. Sources gs, news and oth	isk rating provides an ove of how much of a compar is to be reviewed include corp ther media, NGO reports/web	ny's exposure to ESG corate publications and sites, multi-sector	more risk is uni	managed, the	score is the sum higher ESG risk	is scored.	
		mpany feedbac uality & peer rev	ck, ESG controversies, issuer views.	feedback on draft ESG	NEGL 0-10	Low 10-20	Medium 20-30	High 30-40	Severe 40+
ESG Book	positioned to the principle helps explair over-weightin	outperform o of financial m n future risk-a	sustainable companies the companies the long term. The materiality including inform digusted performance. Ma ith higher materiality and erly basis.	nethodology considers nation that significantly ateriality is applied by	The total ESG scores using m	score is calcu ateriality-base	lated as a weight ed weights. The s ndicating better p	ed sum of the score is scaled	features
<u>MSCI</u>	MSCI ESG r	atings aim to	measure a company's m	anagement of financially their exposure to ESG ris	relevant ESG ris	ks and opport they manage	tunities. It uses a those risks relat	rules-based r	nethodology to
	AAA	8.571-10.00		·				•	
	AA	7.143-8.570	Leader:	leading its industry in ma	anaging the most si	gnificant ESG r	isks and opportunitie	es	
	Α	5.714-7.142	2						
	BBB	4.286-5.713	3 Average:	a mixed or unexceptional industry peers	al track record of ma	anaging the mo	st significant ESG ri	sks and opportu	nities relative to
	ВВ	2.857-4.285	_	muusiry peers					
	В	1.429-2.856	6					. ===	
	ccc	0.000-1.428	Laggard :	lagging its industry base	d on its high expos	ure and failure t	to manage significar	nt ESG risks	
Moody's ESG solutions	believes that	t a company ir		take into account ESG of nto its business model and medium to long term.					
Refinitiv ESG rating	based on pu	blicly available	e and auditable data. The	e a company's relative ES e score ranges from 0 to are 0 to 25 = poor; >25 to 50 =	100 on relative E	SG performa	nce and insufficie	nt degree of t	
S&P Global				asuring a company's perfossification. The score ran			of ESG risks, op	portunities, ar	nd impacts
Bloomberg	ESG Score		score is based on Bloo	uating the company's aggromberg's view of ESG fina	ıncial materiality.	The score is	a weighted gene	ralized mean	(power mean)
			of Pillar Scores, where	the weights are determin	ed by the pillar p	nonty ranking	i. Values range ii	oni o to to, it) is the best.

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Sureeporn Teewasuwet FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Sureeporn Teewasuwet started covering this stock from 12-Dec-2023

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Master Style	MASTER TB	THB 72.75	BUY	Downside risks to our P/E-based TP include 1) increased competition, 2) a pandemic that results in a lockdown, 3) lower-than-expected utilization rate of new operating beds, 4) higher-than-expected doctor costs and expenses, and 5) a loss contribution from the acquired units.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 23-Feb-2024 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.